Abstract Details

Title Association of Diastolic Dysfunction and Cognitive Impairment in the Framingham Heart Study

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-001

Objective We studied the impact of diastolic dysfunction, the most common form of cardiac dysfunction, on contemporaneous and subsequent brain health.

Background

Diastolic dysfunction is common and modifiable particularly when identified in early stages. The association of diastolic heart failure and development of dementia has not been fully studied. This study will comprehensively evaluate the relationship between diastolic dysfunction, cognition and neuroimaging. If diastolic dysfunction is found to be associated with cognitive impairment, that would suggest diastolic dysfunction is a novel modifiable risk factor for the development of dementia.

Design/Methods We undertook echocardiography on 1,385 dementia-free Framingham Heart Study participants and related isolated diastolic dysfunction to cognitive and neuroimaging outcomes, and to risk of incident dementia.

Results Diastolic dysfunction (higher e/e’ ratio) was associated with poorer executive function, (Similarities (-0.29±0.09, p<0.002), and phonemic fluency (-1.21±0.34, p<0.001)). Persons with moderate to severe diastolic dysfunction had higher white matter hyperintensity (0.29±0.09, p<0.002) and decreased cortical gray (-0.34±0.16, p<0.033). Mild diastolic dysfunction was associated with increased risk of all cause (0.55[0.33,0.93], p<0.025) and Alzheimer’s dementia (0.48[0.26,0.87], p<0.016).

Conclusions

Worsening diastolic dysfunction was associated with poorer cognition, increased vascular brain injury and increased risk for incident dementia. Diastolic dysfunction may be a modifiable risk factor for the development of cognitive impairment and dementia.

Authors/Disclosures
Alicia S. Parker, MD (UT Health San Antonio) PRESENTER	An immediate family member of Dr. Parker has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Sanara Med Tech. An immediate family member of Dr. Parker has stock in Sanara Med Tech. An immediate family member of Dr. Parker has stock in Rochal Industries. An immediate family member of Dr. Parker has stock in Rochal Parnters. The institution of Dr. Parker has received research support from Texas Alzheimer's Research and Care Consortium. The institution of an immediate family member of Dr. Parker has received research support from Rochal Industries. An immediate family member of Dr. Parker has received intellectual property interests from a discovery or technology relating to health care.
Jayandra Himali	Jayandra Himali has nothing to disclose.
	No disclosure on file
	No disclosure on file
Alexa Beiser	Alexa Beiser has nothing to disclose.
Vinutha Ganapathy, MD, MS	Dr. Ganapathy has nothing to disclose.
Leila Saadatpour, MD	Dr. Saadatpour has nothing to disclose.
Jonathan Donnelly, MBBS (Rochester Regional Health - Unity Hospital)	Dr. Donnelly has nothing to disclose.
	No disclosure on file
Sudha Seshadri, MD, FAAN (Glenn Biggs Institute for Alzheimer'S and Neurodegenerative Diseases)	Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Seshadri has received research support from NIH. The institution of Dr. Seshadri has received research support from Alzheimer Association.

��ɫ��

��ɫ��